Halozyme Therapeutics, Inc. (HALO): History, Ownership, Mission, How It Works & Makes Money

Ever wondered about the story behind Halozyme Therapeutics, Inc. (HALO) and how it's making waves in the biotechnology industry? This biopharmaceutical company, with a market cap of $7.58 Billion USD as of April 2025, is focused on developing and commercializing novel oncology therapies. But how exactly did Halozyme reach a record revenue of $1.015 billion in 2024, and what's the secret behind its ENHANZE drug delivery technology that has reached over one million patients? Keep reading to discover the history, ownership, mission, and financial strategies that drive Halozyme's success.

Halozyme Therapeutics, Inc. (HALO) History

Halozyme Therapeutics, Inc. Founding Timeline

Year established

The company was founded in 1998.

Original location

The company was originally located in San Diego, California.

Founding team members

The founding team included Gregory Frost, who served as CEO.

Initial capital/funding

Details regarding the initial capital and funding for the company's establishment are not readily available in the provided search results.

Halozyme Therapeutics, Inc. Evolution Milestones

Halozyme Therapeutics, Inc. Transformative Moments

Halozyme has undergone several transformative moments that have shaped its trajectory:

• Strategic Shift to Enhanze Technology: A key transformative moment was the strategic focus on the Enhanze drug delivery technology. This platform allows for the subcutaneous delivery of drugs that would otherwise need to be administered intravenously.
• Key Acquisitions: The acquisitions of Ulterra Dermatology in 2019 and Antares Pharma in 2022 significantly broadened Halozyme's product offerings and technological capabilities. The Antares Pharma acquisition, valued at approximately $960 million, was particularly transformative, bringing auto-injector technology and a portfolio of approved products.
• Partnerships with Major Pharmaceutical Companies: Collaborations with industry giants like Roche have validated Halozyme's Enhanze technology and provided substantial revenue through milestone payments and royalties.
• Regulatory Milestones: FDA approval of Hylenex was a pivotal moment, establishing the company as a leader in drug delivery technology.

To gain further insights into the company's financial standing, explore this comprehensive analysis: Breaking Down Halozyme Therapeutics, Inc. (HALO) Financial Health: Key Insights for Investors

Halozyme Therapeutics, Inc. (HALO) Ownership Structure

Understanding Halozyme Therapeutics, Inc.'s ownership structure provides key insights into its governance and strategic direction. A mix of institutional and individual shareholders influences the company.

Halozyme Therapeutics, Inc.'s Current Status

Halozyme Therapeutics, Inc. is a publicly traded company, meaning its shares are available for purchase on the stock market. It is listed on the NASDAQ under the ticker symbol HALO.

Halozyme Therapeutics, Inc.'s Ownership Breakdown

The ownership of Halozyme Therapeutics is distributed among various types of shareholders. Here's a breakdown:

Halozyme Therapeutics, Inc.'s Leadership

The leadership team guides the strategic direction and operational execution of Halozyme Therapeutics. Key members of the leadership team as of April 2025 include:

• Dr. Helen I. Torley: President and Chief Executive Officer
• Nicole LaBrosse: Senior Vice President, Chief Financial Officer
• Dr. Athena Countouriotis: Senior Vice President, Chief Medical Officer

For more insight into the company's goals, explore Mission Statement, Vision, & Core Values of Halozyme Therapeutics, Inc. (HALO).

Halozyme Therapeutics, Inc. (HALO) Mission and Values

Halozyme Therapeutics aims to improve patient lives by developing novel and innovative therapies. Their core values emphasize innovation, collaboration, and a commitment to making a meaningful difference in healthcare.

Halozyme's Core Purpose

Official mission statement

Halozyme Therapeutics' mission statement is to improve the lives of patients through innovative and scientifically driven solutions. This involves:

• Developing and commercializing novel therapies that address unmet medical needs.
• Leveraging their proprietary ENHANZE® technology to enhance the delivery and effectiveness of other drugs.
• Collaborating with leading pharmaceutical and biotechnology companies to expand the reach of their technology.

Vision statement

Halozyme envisions a future where their innovative technologies and therapies significantly improve patient outcomes and transform the treatment landscape. This includes:

• Becoming a leader in drug delivery and biologics innovation.
• Expanding the application of the ENHANZE® technology across a wide range of therapeutic areas.
• Creating value for patients, partners, and shareholders through scientific excellence and strategic execution.

Company slogan/tagline

While Halozyme does not have a singular, publicly promoted slogan, their corporate communications often highlight themes of innovation, partnership, and patient focus. These themes underscore their commitment to advancing healthcare through scientific breakthroughs and collaborative efforts.

To learn more about the investors of Halozyme Therapeutics, Inc., check out this insightful piece: Exploring Halozyme Therapeutics, Inc. (HALO) Investor Profile: Who’s Buying and Why?

Halozyme Therapeutics, Inc. (HALO) How It Works

Halozyme Therapeutics, Inc. operates as a biopharmaceutical company focused on developing and commercializing novel oncology therapies and drug delivery technologies.

Halozyme's Product/Service Portfolio

Halozyme's Operational Framework

Halozyme operates through two primary business segments:

• Oncology: Focused on the development and commercialization of cancer therapies.
• ENHANZE® Technology: Involves the licensing of its ENHANZE® drug delivery technology to other pharmaceutical and biotechnology companies.

Here's a breakdown of their operational processes:

• Research and Development: Halozyme invests in R&D to discover and develop innovative therapies and drug delivery technologies. A significant focus is on oncology and improving drug delivery through the ENHANZE® platform.
• Licensing Agreements: A core part of Halozyme's business model involves out-licensing the ENHANZE® technology to other companies. These agreements typically include upfront payments, milestone payments, and royalties on sales of products using ENHANZE®.
• Manufacturing and Supply Chain: Halozyme relies on third-party manufacturers to produce its products. They manage the supply chain to ensure a consistent supply of materials and finished goods.
• Clinical Trials: For its oncology products, Halozyme conducts clinical trials to evaluate the safety and efficacy of its therapies. These trials are essential for regulatory approval and eventual commercialization.
• Regulatory Affairs: Halozyme works closely with regulatory agencies like the FDA in the United States and the EMA in Europe to obtain approval for its products.
• Commercialization: Once a product is approved, Halozyme commercializes it through its sales and marketing teams or through partnerships with other companies.

To gain more insights into Halozyme's financial performance, check out: Breaking Down Halozyme Therapeutics, Inc. (HALO) Financial Health: Key Insights for Investors

Halozyme's Strategic Advantages

Halozyme's success is underpinned by several strategic advantages:

• ENHANZE® Technology: The ENHANZE® platform provides a competitive edge by enabling subcutaneous delivery of drugs that would otherwise require intravenous administration. This improves patient convenience and reduces healthcare costs.
• Strong Patent Portfolio: Halozyme has a robust patent portfolio protecting its ENHANZE® technology and other innovations, providing a barrier to entry for competitors.
• Strategic Collaborations: Halozyme has established partnerships with leading pharmaceutical companies, validating its technology and expanding its market reach.
• Focus on Innovation: Halozyme's commitment to research and development allows it to stay at the forefront of drug delivery and oncology, creating new opportunities for growth.
• Experienced Management Team: Halozyme's management team has a proven track record of success in the biotechnology industry, providing strong leadership and strategic direction.

Halozyme Therapeutics, Inc. (HALO) How It Makes Money

Halozyme Therapeutics, Inc. primarily generates revenue by developing and commercializing drug delivery technologies, with a focus on its ENHANZE® technology platform, which enables subcutaneous delivery of injectable drugs that are typically administered intravenously.

Halozyme's Revenue Breakdown

Halozyme's Business Economics

The business economics of Halozyme are centered on its ENHANZE® technology, which improves the delivery and effectiveness of other companies' drugs. This creates several economic advantages:

• High-Margin Revenue: Royalties and license fees from ENHANZE®-enabled products provide high-margin revenue streams.
• Partnership Model: Collaborations with pharmaceutical companies reduce the financial risk associated with drug development, as partners bear the costs of clinical trials and regulatory approvals.
• Recurring Revenue: Once a partner's ENHANZE®-based product is approved and launched, Halozyme receives ongoing royalty payments, creating a recurring revenue stream.
• Competitive Advantage: The ENHANZE® technology offers a competitive edge by improving drug delivery, potentially extending product life cycles, and enhancing patient convenience.

These factors combine to create a business model with strong profitability and growth potential. Learn more about the Mission Statement, Vision, & Core Values of Halozyme Therapeutics, Inc. (HALO).

Halozyme's Financial Performance

Halozyme's financial performance in 2024 demonstrates a strong and growing business. Here are some key highlights:

• Revenue Growth: Total revenue for 2024 was $782.6 million, an increase of 14% compared to $688.2 million in 2023. This growth was primarily driven by increased royalty revenues from existing partnered products and milestones from collaborations.
• Net Income: The company reported net income of $274.5 million, or $2.05 per diluted share, compared to a net income of $173.9 million, or $1.24 per diluted share, for the prior year.
• Cash Position: Halozyme maintains a healthy cash position, with approximately $708.9 million in cash, cash equivalents, and marketable securities as of December 31, 2024. This strong liquidity provides financial flexibility for strategic investments and acquisitions.
• Guidance: For 2025, Halozyme projects revenues between $840 million and $910 million.

Halozyme's revenue is significantly influenced by royalty revenues on sales of products using their ENHANZE platform. For instance, a substantial portion of their revenue comes from royalties on sales of products like DARZALEX FASPRO. These royalties are based on a percentage of the net sales of these partnered products.

The company has been actively managing its capital structure, including share repurchase programs and debt repayments, to enhance shareholder value. These activities reflect a strategic approach to capital allocation and financial management.

Halozyme Therapeutics, Inc. (HALO) Market Position & Future Outlook

Halozyme Therapeutics is strategically positioned in the biopharmaceutical industry with its ENHANZE® drug delivery technology, which enhances the delivery of injectable drugs. As of April 2025, the company's focus remains on expanding its partnerships and developing new applications for its technology to maintain a competitive edge and drive future growth. More information about the company's financial health can be found here: Breaking Down Halozyme Therapeutics, Inc. (HALO) Financial Health: Key Insights for Investors

Competitive Landscape

Opportunities & Challenges

Industry Position

Halozyme's industry position can be further clarified by the following points:

• Halozyme is a leader in the drug delivery technology space, particularly with its ENHANZE® platform.
• The company's technology is used to improve the delivery and efficacy of injectable drugs, making treatments more convenient for patients.
• Halozyme generates revenue primarily through royalties and milestones from its partnerships with pharmaceutical companies. For example, the company reported total revenues of $697.7 million for the fiscal year 2024, representing a 15.3% increase compared to $605.2 million for the fiscal year 2023.
• Halozyme strategically focuses on collaborating with major pharmaceutical players to maximize the reach and impact of its technology.